GILD Company Profile and Key Details
Gilead Sciences, Inc.
GILD Stock Price Chart
Stock Price Today
Gilead Sciences, Inc. (GILD) stock declined over -0.40%, trading at $97.99 on NASDAQ, down from the previous close of $98.38. The stock opened at $98.38, fluctuating between $97.06 and $98.47 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Information
| Employees | 18000 |
| Beta | 0.19 |
| Sales or Revenue | $27.12B |
| 5Y Sales Change% | 0.275% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently Asked Questions
Gilead Sciences, Inc. (NASDAQ: GILD) stock price is $97.99 in the last trading session. During the trading session, GILD stock reached the peak price of $98.47 while $97.06 was the lowest point it dropped to. The percentage change in GILD stock occurred in the recent session was -0.4% while the dollar amount for the price change in GILD stock was -$0.39.
The NASDAQ listed GILD is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Gilead Sciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Sandra Patterson
Senior Vice President, Corporation Controller & Principal Accounting Officer
Ms. Deborah H. Telman
Executive Vice President of Corporation Affairs, Gen. Counsel & Corp. Sec.
Dr. Merdad V. Parsey M.D., Ph.D.
Chief Medical Officer
Ms. Jacquie Ross C.F.A.
Vice President of Investor Relations
Dr. Michael Quigley Ph.D.
Senior Vice President of Research Biology
Ms. Diane E. Wilfong
Senior Vice President, Corporation Controller & Chief Accounting Officer
Mr. Daniel P. O'Day
Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson
Executive Vice President & Chief Financial Officer
Ms. Johanna Mercier
Chief Commercial Officer
Dr. Linda Slanec Higgins Ph.D.
Senior Vice President & Head of External Innovation
Ms. Jyoti K. Mehra
Executive Vice President of HR
GILD's closing price is 57.87% higher than its 52-week low of $62.07 where as its distance from 52-week high of $99.45 is -1.47%.
Number of GILD employees currently stands at 18,000.
Official Website of GILD is: https://www.gilead.com
GILD could be contacted at phone 650 574 3000 and can also be accessed through its website. GILD operates from 333 Lakeside Drive, Foster City, CA 94404, United States.
GILD stock volume for the day was 6.15M shares. The average number of GILD shares traded daily for last 3 months was 7.12M.
The market value of GILD currently stands at $122.12B with its latest stock price at $97.99 and 1.25B of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com